Hämatologie und Onkologie mit Palliativmedizin

Mitgliedschaft in Fachgesellschaften

• Deutsche Krebsgesellschaft e.V.
  • seit 1996 als Mitglied
  • seit 1996 als Mitglied der Arbeitsgemeinschaft experimentelle Krebsforschung (AEK)
  • seit 2007 als Mitglied der Arbeitsgemeinschaft Internistische Onkologie (AIO)
    - seit 25.11.2019 als Vorsitzende der AIO
    - seit 2007 als Mitglied der Leitgruppe Translationale Forschung, als Sprecherin 2010 - 2017
    - seit 2007als Mitglied der Leitgruppe Kolorektales Karzinom, als Sprecherin 2016 - 2018
  • seit 2010 als Sprecher Leitgruppe Translationale Forschung
  • seit 2016 als Sprecher Leitgruppe kolorektales Karzinom
• Deutsche Gesellschaft für Verdauungs- und Stoffwechselerkrankungen (DGVS)
  • seit 2007 als Mitglied, Sektionseditor Onkologie Zeitschrift für Gastroenterologie (Sektion Onkologie)
• Deutsche Krebshilfe e.V.
  • seit 2017 berufenes Mitglied im Fachausschuss „Versorgungsmaßnahmen und –forschung mit gesundheits-/strukturpolitischer Ausrichtung“ 
  • Mitglied des Lenkungsausschusses des Leitlinienprogramms Onkologie

• Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.
  Seit 2017 als Mitglied

•  

  ESMO
  seit 2018 als Mitglied

• AdP e.V.
  Arbeitskreis der Pankreatektomierten
  - seit 2020 als Wissenschaftlicher Beirat

• Fakultätsrat Medizinische Fakultät Ruhr-Universität Bochum
  - seit 10/2020 als Mitglied

Nöpel-Dünnebacke S, Jütte H, Denz R, Feder IS, Kraeft AL, Lugnier C, Teschendorf C, Collette D, Böhner H, Engel L, Mueller L, Hartmann F, Kaiser U, Bruch HR, Hollerbach S, Arnold D, Timmesfeld N, Tannapfel A, Reinacher-Schick A.
Causes of mortality in elderly UICC stage III colon cancer (CC) patients--Tumor-related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry.
Cancer Med. 2022 Feb 11. doi: 10.1002/cam4.4540.

Grünwald V, Bethge W, Blohmer JU, Burkhardt B, Dirksen U, Ebert M, Gschwend J, Gutzmer R, Henn D, Hermann K, Isbary G, Klußmann JP, Knauf W, Krause M, Luntz S, Paradies K, Piso P, Ryll B, Schmidt G, Sinn M, Stintzing S, Wedding U, Wesselmann S, Reinacher-Schick A.
Current clinical research landscape in Germany-an interdisciplinary position paper.
Onkologe (Berl). 2022 Jan 28:1-4. doi: 10.1007/s00761-022-01106-x. Online ahead of print.PMID: 35106031 Free PMC article. Review. German.

Modest DP, Karthaus M, Fruehauf S, Graeven U, Müller L, König AO, Fischer von Weikersthal L, Caca K, Kretzschmar A, Goekkurt E, Haas S, Kurreck A, Stahler A, Held S, Jarosch A, Horst D, Reinacher-Schick A, Kasper S, Heinemann V, Stintzing S, Trarbach T.
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212).
J Clin Oncol. 2022 Jan 1;40(1):72-82. doi: 10.1200/JCO.21.01332. Epub 2021 Sep 17.PMID: 34533973

Stasik S, Mende M, Schuster C, Mahler S, Aust D, Tannapfel A, Reinacher-Schick A, Baretton G, Krippendorf C, Bornhäuser M, Ehninger G, Folprecht G, Thiede C.Front
Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer.
Genet. 2022 Jan 5;12:811291. doi: 10.3389/fgene.2021.811291. eCollection 2021.PMID: 35069704 Free PMC article.

Stasik S, Mende M, Schuster C, Mahler S, Aust D, Tannapfel A, Reinacher-Schick A, Baretton G, Krippendorf C, Bornhäuser M, Ehninger G, Folprecht G, Thiede C.
Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer. 2022 Front. Genet. 12:811291. doi: 10.3389/fgene.2021.811291

Lorenzen S, Reinacher-Schick A, Masetti M.
Modern concepts of systemic treatment for adjuvant and palliative treatment of locally advanced or metastasized esophageal cancer
Chirurg. 2021 Dec;92(12):1085-1093. doi: 10.1007/s00104-021-01476-9. Epub 2021 Aug 13.PMID: 34387700 Review. German.

Nöpel-Dünnebacke S, Conradi LC, Reinacher-Schick A, Ghadimi M.
Influence of molecular markers on oncological surgery of colorectal cancer.
Chirurg. 2021 Nov;92(11):986-995. doi: 10.1007/s00104-021-01486-7. Epub 2021 Aug 27.PMID: 34448902

Overheu O, Quast DR, Schmidt WE, Sakinç-Güler T, Reinacher-Schick A.
Low Serological Prevalence of SARS-CoV-2 Antibodies in Cancer Patients at a German University Oncology Center
Oncol Res Treat. 2021 Nov 1:1-6. doi: 10.1159/000520572. Online ahead of print.PMID: 34724665 Free PMC article

Klimas R, Sgodzai M, Motte J, Mohamad N, Renk P, Blusch A, Grüter T, Pedreiturria X, Gobrecht P, Fischer D, Schneider-Gold C, Reinacher-Schick A, Tannapfel A, Yoon MS, Gold R, Pitarokoili K.
Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis.
Brain Commun. 2021 Oct 9;3(4):fcab238. doi: 10.1093/braincomms/fcab238. eCollection 2021.PMID: 34708206 Free PMC article.

Noepel-Duennebacke S, Juette H, Schulmann K, Graeven U, Porschen R, Stoehlmacher J, Hegewisch-Becker S, Raulf A, Arnold D, Reinacher-Schick A, Tannapfel A.
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
J Cancer Res Clin Oncol. 2021 Oct;147(10):3063-3072. doi: 10.1007/s00432-021-03559-w. Epub 2021 Mar 6. PMID: 33675399; PMCID: PMC8397637.

Modest DP, Karthaus M, Fruehauf S, Graeven U, Müller L, König AO, Fischer von Weikersthal L, Caca K, Kretzschmar A, Goekkurt E, Haas S, Kurreck A, Stahler A, Held S, Jarosch A, Horst D, Reinacher-Schick A, Kasper S, Heinemann V, Stintzing S, Trarbach T.
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212).
J Clin Oncol. 2021 Sep 17:JCO2101332. doi: 10.1200/JCO.21.01332. Epub ahead of print. PMID: 34533973.

Folprecht G, Reinacher-Schick A, Weitz J, Lugnier C, Kraeft AL, Wisser S, Aust DE, Weiss L, von Bubnoff N, Kramer M, Thiede C, Tannapfel A.
The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217).
Clin Colorectal Cancer. 2021 Sep 15:S1533-0028(21)00091-8. doi: 10.1016/j.clcc.2021.09.005. .PMID: 34772609

Nöpel-Dünnebacke S, Conradi LC, Reinacher-Schick A, Ghadimi M.
Einfluss der Molekularpathologie auf die onkologische Chirurgie des kolorektalen Karzinoms [Influence of molecular markers on oncological surgery of
colorectal cancer].
Chirurg. 2021 Aug 27. German. doi: 10.1007/s00104-021-01486-7. Epub ahead of print. PMID: 34448902.

Stefanie Noepel-Duennebacke, Henrik Juette Celine Lugnier, Dominik Paul Modest, Uwe Martens,Renate Klaassen-Mielke, Volker Heinemann, Thomas Seufferlein, Michael Geissler, Andrea Tannapfel, Anke Reinacher-Schick,
Iris Tischof
Histopathologic Regression and Survival in RAS Wildtype Metastatic Colorectal Cancer Under First-Line Treatment – Subgroup Analysis of the VOLFI Trial (AIO-KRK-0109)
International Journal of Clinical Oncology and Cancer. Research 2021; 6(3): 130-135, http://www.sciencepublishinggroup.com/j/ijcocr, doi: 10.11648/j.ijcocr.20210603.15, ISSN: 2578-9503 (Print); ISSN: 2578-9511 (Online)

Haas M, Waldschmidt DT, Stahl M, Reinacher-Schick A, Freiberg-Richter J, Fischer von Weikersthal L, Kaiser F, Kanzler S, Frickhofen N, Seufferlein T, Dechow T, Mahlberg R, Malfertheiner P, Illerhaus G, Kubicka S, Abdul-Ahad A, Snijder R, Kruger S, Westphalen CB, Held S, von Bergwelt-Baildon M, Boeck S, Heinemann V.
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
Eur J Cancer. 2021 Mar;146:95-106. doi: 10.1016/j.ejca.2020.12.029. Epub 2021 Feb 12.PMID: 33588150 Clinical Trial.

Höhn P, Braumann C, Nöpel-Dünnebacke S, Munding J, Uhl W, Luu AM.
Recurrence of Pancreatic Ductal Adenocarcinoma after Complete Histopathological Remission Caused by FOLFIRINOX.
Visc Med. 2021, Mar;37(2):149-153. doi: 10.1159/000509231. Epub 2020 Jul 31. PMID:
33981756; PMCID: PMC8077528.

Fietkau R, Grützmann R, Wittel UA, Croner RS, Jacobasch L, Neumann UP, Reinacher-Schick A, Imhoff D, Boeck S, Keilholz L, Oettle H, Hohenberger WM, Golcher H, Bechstein WO, Uhl W, Pirkl A, Adler W, Semrau S, Rutzner S, Ghadimi M, Lubgan D.
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
Strahlenther Onkol. 2021 Jan;197(1):8-18. doi: 10.1007/s00066-020-01680-2. Epub 2020 Sep 10.PMID: 32914237 Free PMC article. Clinical Trial.

Lueong SS, Herbst A, Liffers ST, Bielefeld N, Horn PA, Tannapfel A, Reinacher-Schick A, Hinke A, Hegewisch-Becker S, Kolligs FT, Siveke JT.
Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
Clin Chem. 2020 Dec 1;66(12):1510-1520. doi: 10.1093/clinchem/hvaa223. PMID: 33257977.

Siveke T, Hinke A, Hegewisch-Becker S, Kolligs FT, Bielefeld J, Horn PA, Tannapfel A, Reinacher-Schick A, Lueong SS, Herbst A, Liffers S-T, Nicola
Trial mutant metastatic colorectal cancer from the phase 3 AIO KRK0207 Serial circulating tumor DNA mutational status in patients with KRAS
CLINCHEM/2019/315812 [R4], Article, KRAS ctDNA; ddPCR;

Kurreck A, Geissler M, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Stintzing S, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Modest DP.
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
J Cancer Res Clin Oncol. 2020 Oct;146(10):2681-2691. doi: 10.1007/s00432-020-03257-z. Epub 2020 May 24.PMID: 32449003 Free PMC article. Clinical Trial.

Lorenzen S, Lordick F, Loosen SH, Tacke F, Trautwein C, Roderburg C, Ettrich TJ, Perkhofer L, Reinacher-Schick A, Stein A.
Current status of immunotherapy in gastrointestinal malignancies.
Z Gastroenterol. 2020 Jun;58(6):542-555. doi: 10.1055/a-1071-8322. Epub 2020 Feb 4.PMID: 32018315 English

Noepel-Duennebacke S, Juette H, Feder IS, Kluxen L, Basara N, Hiller W, Herzog T, Klaassen-Mielke R, Mueller L, Senkal M, Engel L, Teschendorf C, Trenn G, Verdoodt B, Wolters H, Uhl W, Reinacher-Schick A, Tannapfel A.Z
High microsatellite instability (MSI-H) is associated with distinct clinical and molecular characteristics and an improved survival in early Colon cancer (CC); real world data from the AIO molecular registry Colopredict Plus.
Gastroenterol. 2020 Jun;58(6):533-541. doi: 10.1055/a-1156-4433. Epub 2020 Jun 16.PMID: 32544965 English.

Reinacher-Schick A, Tannapfel A.
Viszeralonkologie 2020.
Z Gastroenterol. 2020 Jun;58(6):532. doi: 10.1055/a-1153-2848. Epub 2020 Jun 16.PMID: 32544964

Wörmann B, Bokemeyer C, Burmeister T, Köhne CH, Schwab M, Arnold D, Blohmer JU, Borner M, Brucker S, Cascorbi I, Decker T, de Wit M, Dietz A, Einsele H, Eisterer W, Folprecht G, Hilbe W, Hoffmann J, Knauf W, Kunzmann V, Largiadèr CR, Lorenzen S, Lüftner D, Moehler M, Nöthen MM, Pox C, Reinacher-Schick A, Scharl A, Schlegelberger B, Seufferlein T, Sinn M, Stroth M, Tamm I, Trümper L, Wilhelm M, Wöll E, Hofheinz RD.
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.
Oncol Res Treat. 2020;43(11):628-636. doi: 10.1159/000510258. Epub 2020 Oct 23.PMID: 33099551 Free article. Review.

Kallenbach-Thieltges A, Großerueschkamp F, Jütte H, Kuepper C, Reinacher-Schick A, Tannapfel A, Gerwert K.
Label-free, automated classification of microsatellite status in colorectal cancer by infrared imaging.
Sci Rep. 2020 Jun 23;10(1):10161. doi: 10.1038/s41598-020-67052-z.PMID: 32576892 Free PMC article.

Attenberger U, Rödel C, Ghadimi M, Piso P, Arnold D, Folprecht G, Geissler M, Hegewisch-Becker S, Heinemann V, Kasper S, Modest D, Reinacher-Schick A, Seufferlein T, Stein A, Stintzing S, Hofheinz RD.
Prerequisites of magnetic resonance imaging for treatment planning in locally advanced rectal cancer - Interdisciplinary recommendations.
Z Gastroenterol. 2020 Jun;58(6):577-582. doi: 10.1055/a-1085-6874. Epub 2020 Jun 16.PMID: 32544967 German.

Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T; POLO Investigators.
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
Ann Oncol. 2019 Dec 1;30(12):1959-1968. (IF: 14.196)

Modest DP,Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S , Ettrich T, Kanzler S°,  Nörenberg D, Ricke J, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Geissler M.
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
J Clin Oncol. 2019 Dec 10;37(35):3401-3411. (IF: 26.303)

Wittel UA, Lubgan D, Ghadimi M, Belyaev O, Uhl W, Bechstein WO, Grützmann R, Hohenberger WM, Schmid A, Jacobasch L, Croner RS, Reinacher-Schick A, Hopt UT, Pirkl A, Oettle H, Fietkau R, Golcher H.
Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.
BMC Cancer. 2019 Oct 22;19(1):979, (IF: 3.288)

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
N Engl J Med. 2019 Jun 2. (IF: 70,670)

Haltaufderheide J, Wäscher S, Bertlich B, Vollmann J, Reinacher-Schick, A., Schildmann J.
"I need to know what makes somebody tick …": Challenges and Strategies of Implementing Shared Decision-Making in Individualized Oncology.
Oncologist. 2019 Apr;24(4):555-562. (IF: 5,252)

Tannapfel, A, Reinacher-Schick, A
Immunotherapy in Gastrointestinal Cancer: Where Do We Stand?
Visc Med 2019 Mar;35(1):1-2. doi: 10.1159/000497294. Epub 2019 Feb 8.
PMID: 31312643 (IF: 1,989)

Tannapfel A, Reinacher-Schick A, Hacker U, Lorenzen S, Möhler M, Vogel A.
Immunotherapy: New Options in Gastrointestinal Cancers?
Visc Med. 2019 Mar;35(1):47-51. doi: 10.1159/000497293. Epub 2019 Feb 14.  (IF: 1,989)
PMID: 31312650

Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H, Janssen KP, König A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, Tannapfel A, Kleger A, Beutel A, Schulte LA, Kornmann M, Ettrich TJ, Seufferlein T.
A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.
Theranostics. 2019 Feb 12;9(5):1280-1287 (IF: 8,063)

Pitarokoili K, Höffken N, Lönneker N, Fisse AL, Trampe N, Gold R, Reinacher-Schick A, Yoon MS.
Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy.
J Neuroimaging. 2019 Jan;29(1):133-139. (IF: 2.080)

Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, Reinacher-Schick A, Uhl W, Seufferlein T.
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
BMC Cancer. 2018 Dec 29;18(1):1298. (IF: 3,288)

Noepel-Duennebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, Reinacher-Schick A.
Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.
Clin Colorectal Cancer. 2018 Dec;17(4):e733-e739. (IF: 3,176)

Stintzing S, Ivanova B, Ricard I, Jung A, Kirchner T, Tannapfel A, Juette H, Hegewisch-Becker S, Arnold D, Reinacher-Schick A.
Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.
Front Oncol. 2018 Nov 8;8:474 (IF: 4,137)

Hegewisch-Becker S, Nöpel-Dünnebacke S, Hinke A, Graeven U, Reinacher-Schick A, Hertel J, Lerchenmüller CA, Killing B, Depenbusch R, Al-Batran S, Lange T, Dietrich G, Tannapfel A, Arnold D
Impact of primary tumor location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab  Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
Eur J Cancer. 2018 Sep;101:105-113 (IF: 6,680)

Luu AM, Herzog T, Hoehn P, Reinacher-Schick A, Munding J, Uhl W, Braumann C.
FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer.
J Gastrointest Oncol. 2018 Apr;9(2):E9-E12. (IF: 1,66)

Ettrich TJ, Ebert M, Lorenzen S, Moehler M, Vogel A, Witkowski L, Seufferlein T, Reinacher-Schick A.
ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].
Z Gastroenterol. 2018 Apr;56(4):384-397. (IF: 1.236)

Salloch S, Otte IC, Reinacher-Schick A, Vollmann J.
Ärztliche Perspektiven auf die Bedeutung von Patientenpräferenzen und die Rolle Angehöriger bei der evidenzbasierten Entscheidungsfindung - eine qualitative Interviewstudie aus der Onkologie.
Z Evid Fortbild Qual Gesundhwes. 2018 Apr;131-132:46-52 (IF: 0,27)

Salloch S, Otte I, Reinacher-Schick A, Vollmann J.
What does physicians' clinical expertise contribute to oncologic decision-making? A qualitative interview study.
J Eval Clin Pract. 2018 Feb;24(1):180-186. (IF: 1.536)

Otte I, Salloch S, Reinacher-Schick A, Vollmann J.
Treatment recommendations within the leeway of clinical guidelines: A qualitative interview study on oncologists' clinical deliberation.
BMC Cancer. 2017 Nov 21;17(1):780. (IF: 3.288)

Schneider-Gold C, Reinacher-Schick A, Ellrichmann G, Gold R.
Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.
Ther Adv Neurol Disord. 2017 Oct;10(10):339-341. (IF: 4.750)

Pitarokoili K, Yoon MS, Kröger I, Reinacher-Schick A, Gold R, Schneider-Gold C.
Severe refractory CIDP: a case series of 10 patients treated with bortezomib.
J Neurol. 2017 Sep;264(9):2010-2020. (IF: 3.783)

Herbst A, Vdovin N, Gacesa S, Philipp A, Nagel D, Holdt LM, Op den Winkel M, Heinemann V, Stieber P, Graeven U, Reinacher-Schick A, Arnold D, Ricard I, Mansmann U, Hegewisch-Becker S, Kolligs FT.
Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.
Int J Cancer. 2017 May 1;140(9):2134-2144. (IF: 7.360)

Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A, Trarbach T, Marschner N, Schmoll HJ, Hinke A, Al-Batran SEW, Arnold D
Qualitiy of life in assessment in patients with metastatic colorectal cancer recieving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.
Ann Oncol. 2016 Dec; 27(12):2203-2210

Behrendt V, Krogias C, Reinacher-Schick A, Gold R, Kleiter I
Bortezomib Treatment for Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis.
JAMA Neurol. 2016 Oct 1;73(10):1251-1253

Faissner S, Lukas C, Reinacher-Schick A, Tannapfel A, Gold R, Kleiter I
Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome.
Neurol Neuroimmunol Neuroinflamm. 2016 Sep 28;3(6):e285. eCollection 2016 Dec.

Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stinzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A
Outcome according to KRAS-, NRAS- ans BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
Ann Oncol. 2016 Sep;27(9):1746-53.

Lorenzen S, Arnold D, Fottner C, Leichsenring J, Moehler M, Seufferlein T, Vogel A, Weber MM, Reinacher-Schick A.
[ASCO-update 2015 - highlights of the 51. meeting of the american society of clinical oncology/ASCO 2015].
Z Gastroenterol. 2016 Feb;54(2):167-72. doi: 10.1055/s-0041-111632. Epub 2016 Feb 8. German.

Schneider R, Schneider C, Büttner R, Reinacher-Schick A, Tannapfel A, Fürst A, Rüschoff J, Jakobeit C, Royer-Pokora B, Möslein G
Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm
Zentralbl Chir. 2015 Dec;140(6):591-9

Höffken N, Leichsenring J, Reinacher-Schick A
Clinically relevant, gender-specific differences in colorectal carcinoma (CRC)
Z Gastroenterol. 2015 Aug;53(8):782-8

Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC,  Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D
Maintenance strategies after initial first-line oxaliplatin/fluoropyrimidine/bevacizumab for patients with metastatic colorectal cancer: AIO 0207, a randomized, open-label, phase 3 trial.
Lancet Oncol. 2015 Oct;16(13):1355-69

Haas M, Boeck SH, Waldschmidt D, Reinacher-Schick A, Freiberg-Richter J, Seufferlein T, Kanzler S, Mahlberg R, Siveke JT, Heinemann V
ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumors - An explorative randomized phase II trial
J Clin Oncol. 2015;33S(15)

Bolz J, Meves SH, Kara K, Reinacher-Schick A, Gold R, Krogias C.
Multiple cerebral infarctions in a young patient with heroin-induced hypereosinophilic syndrome.
J Neurol Sci. 2015 Sep 15;356(1-2):193-5; Int J. Stroke 2015 10 2:402-402

Nöpel-Dünnebacke S, Schulmann K, Reinacher-Schick A, Porschen R, Schmiegel W, Tannapfel A, Graeven U.
Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Z Gastroenterol. 2014 Dec;52(12):1394-401.

El-Mashtoly SF, Petersen D, Yosef HK, Mosig A, Reinacher-Schick A, Kötting C, Gerwert K.
Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy.
Analyst. 2014 Mar 7;139(5):1155-61.

Leichsenring J, Koppelle A, Reinacher-Schick A.
Colorectal Cancer: Personalized Therapy
Gastrointest Tumors, 2014 May;1(4):209-20

Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ.
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
Acta Oncol. 2014 Mar;53(3):392-8.

Kähler G, Reinacher-Schick A
Colorectal Adenoma - Resection Techniques and Surveillance
Viszeralmedizin. 2014 Feb;30(1):8-9

Giessen C, Graeven U, Laubender RP, Modest DP, Schulz C, Porschen R, Schmiegel W, Reinacher-Schick A, Hegewisch-Becker S, Stintzing S, Heinemann V.
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
Ann Oncol. 2013 Dec;24(12):3051-5.

Brand L, Munding J, Pox CP, Ziebarth W, Reiser M, Hüppe D, Schmiegel W, Reinacher-Schick A, Tannapfel A.
ß-Catenin, Cox-2 and p53 immunostaining in colorectal adenomas to predict recurrence after endoscopic polypectomy.
Int J Colorectal Dis. 2013 Aug;28(8):1091-8.

Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heußner P, Hohenberger W, Holstege A, Hübner J, Kolligs F, Kreis M, Lux P, Ockenga J, Porschen R, Post S, Rahner N, Reinacher-Schick A, Riemann JF, Sauer R, Sieg A, Scheppach W, Schmitt W, Schmoll HJ, Schulmann K, Tannapfel A, Schmiegel W.
S3-guideline colorectal cancer version 1.0.
Z Gastroenterol. 2013 Aug;51(8):753-854.

Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U.
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Ann Oncol. 2013 Jun;24(6):1580-7.

Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, Fietkau R, Follmann M, Friess H, Galle P, Geissler M, Glanemann M, Gress T, Heinemann V, Hohenberger W, Hopt U, Izbicki J, Klar E, Kleeff J, Kopp I, Kullmann F, Langer T, Langrehr J, Lerch M, Löhr M, Lüttges J, Lutz M, Mayerle J, Michl P, Möller P, Molls M, Münter M, Nothacker M, Oettle H, Post S, Reinacher-Schick A, Röcken C, Roeb E, Saeger H, Schmid R, Schmiegel W, Schoenberg M, Siveke J, Stuschke M, Tannapfel A, Uhl W, Unverzagt S, van Oorschot B, Vashist Y, Werner J, Yekebas E; Guidelines Programme Oncology AWMF; German Cancer Society eV; German Cancer Aid.
S3- Guideline exocrine pancreatic cancer.
Z Gastroenterol. 2013 Dec;51(12):1395-440

Baraniskin A, Nöpel-Dünnebacke S, Ahrens M, Jensen SG, Zöllner H, Maghnouj A, Wos A, Mayerle J, Munding J, Kost D, Reinacher-Schick A, Liffers S, Schroers R, Chromik AM, Meyer HE, Uhl W, Klein-Scory S, Weiss FU, Stephan C, Schwarte-Waldhoff I, Lerch MM, Tannapfel A, Schmiegel W, Andersen CL, Hahn SA.
Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma.
Int J Cancer. 2013 Jan 15;132(2):E48-57.

Pox C, Schmiegel W, Reinacher-Schick A.
Colorectal carcinoma: what's new.
Dtsch Med Wochenschr. 2012 Dec;137(49):2577-80.

Reinacher-Schick A, Schulmann K, Modest D, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W and Tannapfel A.
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
BMC Cancer. 2012 Aug 9; 12:349.

Modest DP, Reinacher-Schick A, Stintzing S, Giessen C, Tannapfel A, Laubender RP, Brodowicz T, Knittelfelder R, Vrbanec D, Schmiegel W, Heinemann V, Zielinski CC.
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Anticancer Drugs. 2012 Juli; 23(6):666-673.

Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, Kloeppel G, Röcken C, Bitzer M, Boeck S, Endlicher E, Reinacher-Schick A, Schmoor C, Geissler M.
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.
Br J Cancer. 2012 Mar 13;106(6):1033-8.

Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick A, Schwarte-Waldhoff I, Schmiegel W, Hahn SA.
MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL.
Carcinogenesis. 2012 Apr;33(4):732-9.

Matthias P.A. Ebert, Marc Tänzer, Benjamin Balluff, Elke Burgermeister, Antje Karen Kretzschmar, David J. Hughes, Reimo Tetzner, Catherine Lofton-Day, Robert Rosenberg, Anke C. Reinacher-Schick, Karsten Schulmann, Andrea Tannapfel, Ralf Hofheinz, Christoph Röcken, Gisela Keller, Rupert Langer, Katja Specht, Rainer Porschen, Jan Stöhlmacher-Williams, Tibor Schuster, Philipp Ströbel, Roland M. Schmid.
TFAP2E/DKK4 and Chemoresistance in Colorectal Cancer.
N Engl J Med, 2012 Jan 5;366(1):44-53.

Munding J, Ziebarth W, Pox CP, Ladigan S, Reiser M, Hüppe D, Brand L, Schmiegel W, Tannapfel A, Reinacher-Schick AC.
The influence of 5-Aminosalicylic acid on the progression of colorectal adenomas via the ß-catenin signaling pathway.
Carcinogenesis. 2012 Mar;33(3):637-43

Kampfenkel T, Tischoff I, Bonhag H, Eckardt M, Schmiegel W, Tannapfel A, Reinacher-Schick A, Viebahn R.
Chemotherapy-associated steatohepatitis in patients with colorectal cancer and surgery on hepatic metastasis: clinical validation of a histopathological scoring system and preoperative risk assessment.
Z Gastroenterol. 2011 Oct;49(10):1407-11.

Pohl M, Werner N, Munding J, Tannapfel A, Graeven U, Nickenig G, Schmiegel W, Reinacher-Schick A.
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Z Gastroenterol. 2011 Oct;49(10):1398-406.

Baraniskin A, Munding J, Schulmann K, Meier D, Porschen R, Arkenau HT, Graeven U, Schmiegel W, Tannapfel A, Reinacher-Schick A.
Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Clin Colorectal Cancer. 2011;10(1):24-9.

Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R
Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.
Blood. 2011;117(11):3140-6.

Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky T, Weihrauch M, Crèmer B, Kashkar H, Odenthal M, Schmiegel W, Hallek M, Hacker U
Identification of Serum Angiopoietin-2 as a Biomarker for Clinical Outcome of Colorectal Cancer Patients Treated with Bevacizumab-Containing Therapy
Br J Cancer, 2010;103(9):1407-14

Michael Pohl, Yvonne Radacz, Nicole Pawlik, Anna Schoeneck, Stephan E. Baldus, Johanna Munding, Wolff Schmiegel, Irmgard Schwarte-Waldholff and Anke Reinacher-Schick
Smad4 mediates mesenchymal-epithelial reversion in SW480 colon carcinoma cells
Anticancer Res., 2010;30:2603-2614

Wieser M, Sauerland S, Arnold D, Schmiegel W, Reinacher-Schick A
Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials
BMC Cancer, 2010;10:309

Weiß JV, Klein-Scory S, Kübler S, Reinacher-Schick A, Stricker I, Schmiegel W, Schwarte-Waldhoff I
Soluble E-cadherin as a serum biomarker candidate: Elevated levels in late stage colorectal carcinoma patients and in FAP.
Int J Cancer. 2010 May 5. Feb 25;10:70.

Trarbach T, Reinacher-Schick A, Hegewisch-Becker S, Vanhoefer U, Frieling T, Lehnert L, Schmiegel W, Graeven U.
Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the arbeitsgemeinschaft internistische onkologie (AIO).
Onkologie. 2010;33(3):89-93.

Klein-Scory S, Kubler S, Diehl H, Eilert-Micus C, Reinacher-Schick A, Stuhler K, Warscheid B, Meyer HE, Schmiegel W, Schwarte-Waldhoff I.
Immunoscreening of the extracellular proteome of colorectal cancer cells.
BMC Cancer. 2010 Feb 25;10(1):70.

Salloch H*, Reinacher-Schick A*, Schulmann K, Pox C, Willert J, Tannapfel A, Heringlake S, Goecke TO, Aretz S, Stemmler S, Schmiegel W.
Truncating mutations in Peutz-Jeghers syndrome are associated with more polyps, surgical interventions and cancers.
Int J Colorectal Dis. 2010 Jan;25(1):97-107.
(*these authors contributed equally to the work and should be considered first authors)